v3.25.2
Segment Reporting
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Segment Reporting

15. Segment Reporting

 

The Company manages its business activities on a consolidated basis and operate as a single operating and reportable segment: Syndax Pharmaceuticals. The Company primarily derives revenue in the United States through milestone revenue and product sales on the approved products, Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr). The accounting policies of the segment are the same as those described in Note 3 – Summary of Significant Accounting Policies.
 

To assess performance, the Company’s Chief Operating Decision Maker, or CODM, Michael Metzger, uses consolidated net loss as the segment’s measure of segment profit or loss. The CODM uses net loss in the budget and forecasting process and considers budget-to actual variances on a quarterly bases when making decisions about the allocation of operating and capital resources.

The following table provides the operating financial results of our biopharmaceutical cancer therapeutics segment:

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

June 30, 2025

 

 

 

 

 

 

 

 

 

 

 

 

Total Revenue

 

$

37,958

 

 

$

3,500

 

 

$

57,753

 

 

$

3,500

 

Less: Significant and other segment expenses

 

 

 

 

 

 

 

 

 

 

 

 

Cost of product sales

 

 

1,279

 

 

 

—

 

 

 

2,164

 

 

 

—

 

Research and development expenses

 

 

 

 

 

 

 

 

 

 

 

 

Revumenib-related costs

 

 

28,155

 

 

 

20,439

 

 

 

48,960

 

 

 

51,880

 

Axatilimab-related costs

 

 

9,053

 

 

 

8,503

 

 

 

28,764

 

 

 

14,104

 

Other R&D programs

 

 

1,826

 

 

 

534

 

 

 

2,747

 

 

 

1,500

 

Personnel cost and other expenses

 

 

18,997

 

 

 

14,861

 

 

 

35,528

 

 

 

29,202

 

General and administrative expenses

 

 

 

 

 

 

 

 

 

 

 

 

Commercial-related expenses

 

 

9,914

 

 

 

7,560

 

 

 

20,739

 

 

 

13,392

 

Personnel cost and other expenses

 

 

19,307

 

 

 

4,153

 

 

 

38,389

 

 

 

8,258

 

Other SG&A expenses

 

 

4,993

 

 

 

11,770

 

 

 

9,405

 

 

 

20,099

 

Stock-based compensation

 

 

13,787

 

 

 

9,896

 

 

 

24,167

 

 

 

18,795

 

Royalty interest expense

 

 

7,854

 

 

 

—

 

 

 

15,903

 

 

 

—

 

Interest expense (income), net

 

 

(5,946

)

 

 

(6,239

)

 

 

(13,127

)

 

 

(13,440

)

Other expense, net

 

 

586

 

 

 

86

 

 

 

807

 

 

 

173

 

Segment net loss

 

$

(71,847

)

 

$

(68,063

)

 

$

(156,693

)

 

$

(140,463

)